Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

NCT03910361 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Type2 Diabetes
Non-Alcoholic Fatty Liver Disease

Interventions

DRUG: Evogliptin
DRUG: Pioglitazone

Sponsor

Dong-A ST Co., Ltd.